Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results - Wikidata - awgldk - TriplyDB

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

http://www.wikidata.org/entity/Q24633874

about

Anti-vascular endothelial growth factor for diabetic macular oedema Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration Anti-vascular endothelial growth factor for neovascular age-related macular degeneration Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathologic myopia Treatment schedules for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD Guidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek Experts Clinical Trials in Branch Retinal Vein Occlusion Management of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled Trials Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration Stereotactic radiotherapy for wet age-related macular degeneration: current perspectives Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept Treatment as Required versus Regular Monthly Treatment in the Management of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis Parainflammation, chronic inflammation, and age-related macular degeneration Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?Age-Related Macular Degeneration: Advances in Management and Diagnosis Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development Comparative safety and tolerability of anti-VEGF therapy in age-related macular degeneration Myopic choroidal neovascularisation: current concepts and update on clinical management Combined intravitreal anti-VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis of comparative studies Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel Mechanisms of age-related macular degeneration Optical coherence tomography for the diagnosis of neovascular age-related macular degeneration: a systematic review The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review Optical coherence tomography in retinopathy of prematurity: looking beyond the vessels Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials Geographic Atrophy and Choroidal Neovascularization in the Same Eye: A Review Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelines Early detection of age related macular degeneration: current status Current perspectives on ranibizumab Clinical use of Bevacizumab in treating refractory glaucoma Anti-VEGF therapies in the treatment of choroidal neovascularisation secondary to non-age-related macular degeneration: a systematic review Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema Strategies for Improving Patient Comfort During Intravitreal Injections: Results from a Survey-Based Study.SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration.Restoring visual function to blind mice with a photoswitch that exploits electrophysiological remodeling of retinal ganglion cells.

P2860

Q24193083-E82E4DEE-EAC5-427F-AD82-A47FCF9A873D Q24193614-C604FE75-3A1E-4FD3-84C9-C2984A3AB74E Q24194251-F22FAD23-BAFF-4F04-AF68-1BB96236B7EF Q24194332-3BC3C154-B705-41AD-BF80-A74F40535EA2 Q26472033-59059238-419C-4253-83FD-D9F1EAD05C9B Q26744068-DE80A62A-678D-496B-BD5D-7EA04B9904E6 Q26748731-21B94F3C-2644-4246-872B-5ECEA4C21B64 Q26749615-721EE041-A50F-4BA2-AFF9-4C3BC35F8DA9 Q26767092-F4C2774A-EDD2-434A-8307-C1CEC7172A50 Q26767095-080250B1-3B5E-4634-B0E0-FF00B688AEAF Q26771522-1B348750-EC15-441A-AB1E-7DCA8F764E45 Q26778521-041F10D0-87C2-42E6-9EFF-D80757A8ED0C Q26785646-89C56A4B-F365-4084-A319-15C909D98979 Q26786766-143C7635-380A-4EED-9AAC-7253F5A011DD Q26787156-CEB9A3A2-3112-41B5-8195-E43A0054DDAD Q26796268-442602D8-C1C8-4420-9D73-EA574FE58D4F Q26799492-CAD7A0C8-9B42-4D93-BC8F-C256B803DA65 Q26799617-507D1BE3-006D-41FF-ACFA-8D7606126CBC Q26824335-4946078C-971D-4C77-8783-E23334EF907D Q26852289-6F57C9FE-7B03-497C-A4BF-3788E38930C5 Q26865884-0BC530ED-6ED1-4730-A3EB-F7303AE3CD01 Q26995216-C31BFBAC-BE7B-4ABB-8E32-ACCEC7EA4620 Q26999836-96B3DD3C-32C2-4D71-A7DC-05BED318AA0C Q27000182-43900D08-1490-422B-9ED3-64C24B4E71DD Q27002615-0DFD4724-2A78-4E69-801E-ED6892D80257 Q27013836-C4B8B9A6-6E05-422C-9C04-85F59458DDF4 Q27023001-8DA6B61D-6756-4869-8959-14851621BF77 Q28049700-2587128E-D098-4469-832B-5266AC660C72 Q28074640-08C9F74C-7836-4C20-B8DC-7A6886D273B1 Q28075473-F89B4955-8D73-480D-AE72-15C228713BD1 Q28076117-385A9D17-6F34-4061-8AC4-887BCF4EE989 Q28082383-4C8F988E-3861-40DE-9223-CC0CA29BEBC9 Q28083405-5B1EED1C-DE58-4E78-B339-667C85109764 Q28083470-F61CDAD9-9F85-4F15-B6BB-9EE9FD2D3F6E Q28236004-6C37145E-2C90-47F1-840E-DE191D92572E Q28292764-2B3345AA-061A-4D25-B4DB-6519E629E5C0 Q30391349-C0FFE508-E6FF-4F17-B524-D184A5B72D6F Q30490738-60B575AD-4143-44B4-AD8F-D259B01D12CE Q30539153-8F862ED9-ED50-46FA-8A87-B5C1BAB189A1 Q30572674-A1541F6D-17E8-4196-9CB4-97A9F4BD917D

P2860

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

http://www.wikidata.org/entity/Q24633874

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Ranibizumab and bevacizumab fo ...... degeneration: two-year results

@ast

Ranibizumab and bevacizumab fo ...... degeneration: two-year results

@en

Ranibizumab and bevacizumab fo ...... degeneration: two-year results

@nl

type

label

Ranibizumab and bevacizumab fo ...... degeneration: two-year results

@ast

Ranibizumab and bevacizumab fo ...... degeneration: two-year results

@en

Ranibizumab and bevacizumab fo ...... degeneration: two-year results

@nl

prefLabel

Ranibizumab and bevacizumab fo ...... degeneration: two-year results

@ast

Ranibizumab and bevacizumab fo ...... degeneration: two-year results

@en

Ranibizumab and bevacizumab fo ...... degeneration: two-year results

@nl

P1433

Q24633874-B31910DD-EBD5-4BC3-908A-FDC6BA152B6E

P1476

Q24633874-2AA8C6AB-9C44-4BC2-9936-B0CEDD4042C5

P2093

Q24633874-542D6301-6F1B-4624-8BCA-BB3B8D09275C

Q24633874-5B181E58-4C29-4420-BE39-7223A9317DDE

Q24633874-5E6E1120-F9D1-45EE-B399-E9EEA579427A

Q24633874-7624F856-E7FA-4DD6-91A8-4BAC344A9ADB

Q24633874-918AA05B-1BD8-4F1F-B62C-6BFB0F8CAEF5

Q24633874-A6D00DC9-22E0-4BFB-AD8F-5A513C6F6461

Q24633874-B7CFEA9B-2640-4FDF-BCC9-5B920CCB46B4

Q24633874-CFA643D2-5EAB-4C3F-AF81-89B7F469289A

Q24633874-FDD2B077-C723-4C02-B805-706B2B7B16AC

P2860

Q24633874-011C2EB0-2FCE-4EAD-BA78-88865155F54A

Q24633874-2D2AEE12-CF73-4D0B-A2DF-1C10B6555025

Q24633874-429F058E-9668-4CDB-8203-D72BF46C0457

Q24633874-52A6E1E8-637C-4E96-88C1-B9F0CB2A8F54

Q24633874-718C0CFF-E8ED-4BB3-8568-E181D59E6E39

Q24633874-82D06535-D7B4-4205-B2C0-C01A456D886E

Q24633874-835FFE7D-9431-4619-8CCE-8A8AA36C4A7B

Q24633874-94CC0CE9-CB79-43D2-B517-C6E8C6590E40

Q24633874-A993A12D-B43C-40AB-8EEA-720BCAACA64F

Q24633874-ADC847BB-150A-43AB-AB41-91ED9CA4D2F7

P304

Q24633874-995FCD89-D982-4EE5-9AC8-ADD15B46BF83

P31

Q24633874-52FD35FF-16C4-4506-B676-485CD5B769E3

P3181

Q24633874-C992F34B-5BD7-474C-986F-76396E8F5B3B

P356

Q24633874-4DB31D7D-E795-48DA-AF66-A451C0587AD0

P407

Q24633874-592CBC3E-ED87-46FE-A8D6-731D2F6AE59F

P433

Q24633874-9BAC9CE1-C41C-4BDF-A6CF-8E2BDFAA70B7

P478

Q24633874-619A6D42-DF9E-445E-9603-56FC6A14D0E5

P577

Q24633874-836A4517-2804-4F4D-9C47-D29E5EB94FB7

P5875

Q24633874-9DD74468-647A-4E5B-9B55-94D7D54394FA

P698

Q24633874-20087019-80F7-4853-B080-923C049B8624

P921

Q24633874-FDFBD0F4-7137-4AE9-A8AA-7AA127158127

P932

Q24633874-765E4384-1B63-48C9-863E-E9D0045DA47A

P3181

P356

J.OPHTHA.2012.03.053

P1433

P1476

Ranibizumab and bevacizumab fo ...... degeneration: two-year results

@en

P2093

Cynthia Toth

http://www.w3.org/2001/XMLSchema#string

Daniel F Martin

http://www.w3.org/2001/XMLSchema#string

Frederick L Ferris

http://www.w3.org/2001/XMLSchema#string

Glenn J Jaffe

http://www.w3.org/2001/XMLSchema#string

Gui-shuang Ying

http://www.w3.org/2001/XMLSchema#string

Juan E Grunwald

http://www.w3.org/2001/XMLSchema#string

Maryann Redford

http://www.w3.org/2001/XMLSchema#string

Maureen G Maguire

http://www.w3.org/2001/XMLSchema#string

Stuart L Fine

http://www.w3.org/2001/XMLSchema#string

P2860

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

Longitudinal data analysis for discrete and continuous outcomes

Ranibizumab for neovascular age-related macular degeneration

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynami

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Adverse effects of anticancer agents that target the VEGF pathway.

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.

Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file.

P304

1388-98

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1093241

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.OPHTHA.2012.03.053

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224896456

http://www.w3.org/2001/XMLSchema#string

P698

22555112

http://www.w3.org/2001/XMLSchema#string

P921

P932

3389193

http://www.w3.org/2001/XMLSchema#string